Clinical trial of fibrinselective thrombolytic pharmaceutical agent «FORTELYZIN®» (III Phase)

S S Markin; Маркин Сергей Сергеевич; A M Semenov; Семенов Андрей Михайлович; V A Markov; Марков Валентин Алексеевич; A A Nizov; Низов Алексей Александрович; E A Ponomarev; Пономарев Эдуард Алексеевич; P A Lebedev; Лебедев Петр Алексеевич

Clinical trial of fibrinselective thrombolytic pharmaceutical agent «FORTELYZIN®» (III Phase)

Authors: Markin SS¹, Semenov AM², Markov VA³, Nizov AA⁴, Ponomarev EA⁵, Lebedev PA⁶
Affiliations:
1. «SuperGene» LLC
2. Peoples' Friendship University of Russia
3. Scientific-Research Institute of Cardiology, Siberian Branch
4. Ryazan Regional Clinical Hospital
5. City Clinical Hospital of Emergency Care № 25
6. M.I. Kalinin Samara Regional Clinical Hospital
Issue: No 1 (2012)
Pages: 105-110
Section: Articles
URL: https://journals.rudn.ru/medicine/article/view/3313
ID: 3313

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

The clinical trial of fibrinselective thrombolytic agent Fortelyzin® (III phase) showed the comparative efficacy and safety with Actilyse® in patients with acute myocardial infarction and obtained data permitted to recommend it for clinical usage.

Keywords

fibrinselective thrombolytic agent, "Fortelyzin®", "Actilyse®", efficacy, safety, patients with acute myocardial infarction

About the authors

S S Markin

«SuperGene» LLC

Email: supergene@mail.ru
ООО «СупраГен»; «SuperGene» LLC

A M Semenov

Peoples' Friendship University of Russia

Email: gendirector@supergene.ru <mailto:gendirector@supergene.ru>
Кафедра экономики предприятия и предпринимательской деятельностиООО «СупраГен»Лужнецкая набережная, 6, стр. 1, Москва, Россия, 119270; Российский университет дружбы народов; Peoples' Friendship University of Russia

References

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register